CY1115524T1 - Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4 - Google Patents

Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4

Info

Publication number
CY1115524T1
CY1115524T1 CY20141100716T CY141100716T CY1115524T1 CY 1115524 T1 CY1115524 T1 CY 1115524T1 CY 20141100716 T CY20141100716 T CY 20141100716T CY 141100716 T CY141100716 T CY 141100716T CY 1115524 T1 CY1115524 T1 CY 1115524T1
Authority
CY
Cyprus
Prior art keywords
human
antibodies against
monoclonic
monoclonic antibodies
against human
Prior art date
Application number
CY20141100716T
Other languages
English (en)
Inventor
Herrera José M Carballido
Vries Jan E De
Christoph Schwaerzler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115524(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417306A external-priority patent/GB0417306D0/en
Priority claimed from GB0417305A external-priority patent/GB0417305D0/en
Priority claimed from GB0417302A external-priority patent/GB0417302D0/en
Priority claimed from GB0417303A external-priority patent/GB0417303D0/en
Priority claimed from GB0417304A external-priority patent/GB0417304D0/en
Priority claimed from GB0417301A external-priority patent/GB0417301D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1115524T1 publication Critical patent/CY1115524T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αντισώματα τα οποία είναι ειδικά για την ανθρώπινη ιντερλευκίνη-4 και η χρήση τους στη θεραπεία παθήσεων που μεσολαβούνται από την IL-4 και/ή την IgE.
CY20141100716T 2004-08-03 2014-09-05 Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4 CY1115524T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0417306A GB0417306D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417305A GB0417305D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417302A GB0417302D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417303A GB0417303D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417304A GB0417304D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417301A GB0417301D0 (en) 2004-08-03 2004-08-03 Organic compounds
EP05769838.3A EP1817343B1 (en) 2004-08-03 2005-08-02 Human monoclonal antibodies against human il-4

Publications (1)

Publication Number Publication Date
CY1115524T1 true CY1115524T1 (el) 2017-01-04

Family

ID=35457817

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100716T CY1115524T1 (el) 2004-08-03 2014-09-05 Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4

Country Status (29)

Country Link
US (2) US7740843B2 (el)
EP (2) EP2327726A3 (el)
JP (1) JP4808712B2 (el)
KR (1) KR101245996B1 (el)
CN (1) CN101001877B (el)
AR (1) AR050044A1 (el)
AU (1) AU2005268932B2 (el)
BR (1) BRPI0514124B8 (el)
CA (1) CA2574289C (el)
CY (1) CY1115524T1 (el)
DK (1) DK1817343T3 (el)
EC (1) ECSP077222A (el)
ES (1) ES2504415T3 (el)
HK (1) HK1109158A1 (el)
HR (1) HRP20140888T1 (el)
IL (1) IL180789A (el)
MA (1) MA28981B1 (el)
MX (1) MX2007001342A (el)
MY (1) MY141851A (el)
NO (1) NO20070854L (el)
NZ (1) NZ552637A (el)
PE (1) PE20060560A1 (el)
PL (1) PL1817343T3 (el)
PT (1) PT1817343E (el)
SG (1) SG155177A1 (el)
SI (1) SI1817343T1 (el)
TN (1) TNSN07036A1 (el)
TW (1) TWI356828B (el)
WO (1) WO2006013087A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868647A4 (en) * 2005-03-24 2009-04-01 Millennium Pharm Inc OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
BR112013019499B1 (pt) 2011-02-04 2023-01-10 Genentech, Inc. Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业（上海）股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology CELL ATLAS OF HEALTHY AND DISEASED BARRIER TISSUE
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CN113677707A (zh) 2019-03-06 2021-11-19 瑞泽恩制药公司 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CN114957472B (zh) * 2020-06-22 2023-10-31 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
CA3241374A1 (en) 2021-12-30 2023-07-06 Gregory GEBA Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0397764A1 (en) 1988-02-02 1990-11-22 Schering Biotech Corporation Method of reducing immunoglobulin e responses
IL96714A0 (en) * 1989-12-20 1991-09-16 Schering Corp Antibody antagonists of human interleukin-4
EP0627002B1 (en) 1992-02-19 1998-09-23 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
HU220103B (hu) 1992-08-20 2001-10-28 Schering-Plough Corp. IL-10 új alkalmazása
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
KR100362340B1 (ko) 1993-09-07 2003-02-26 스미스클라인비이참피이엘시이 인터로이킨-4(il4)매개된질환의치료에유용한재조합il4항체
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20020002132A1 (en) * 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine

Also Published As

Publication number Publication date
JP4808712B2 (ja) 2011-11-02
MX2007001342A (es) 2007-04-02
US7740843B2 (en) 2010-06-22
BRPI0514124B1 (pt) 2017-01-31
AR050044A1 (es) 2006-09-20
EP2327726A3 (en) 2012-07-11
PT1817343E (pt) 2014-09-09
NO20070854L (no) 2007-04-24
SG155177A1 (en) 2009-09-30
EP1817343B1 (en) 2014-06-25
MA28981B1 (fr) 2007-11-01
CA2574289C (en) 2014-09-16
EP1817343A1 (en) 2007-08-15
TW200617024A (en) 2006-06-01
AU2005268932A1 (en) 2006-02-09
CN101001877B (zh) 2012-09-26
ES2504415T3 (es) 2014-10-08
EP2327726A2 (en) 2011-06-01
JP2008507985A (ja) 2008-03-21
IL180789A (en) 2017-01-31
KR101245996B1 (ko) 2013-03-20
PL1817343T3 (pl) 2014-11-28
TNSN07036A1 (en) 2008-06-02
HK1109158A1 (en) 2008-05-30
DK1817343T3 (da) 2014-09-15
IL180789A0 (en) 2007-06-03
SI1817343T1 (sl) 2014-09-30
MY141851A (en) 2010-07-16
PE20060560A1 (es) 2006-06-27
US20080241160A1 (en) 2008-10-02
AU2005268932B2 (en) 2009-06-25
WO2006013087A1 (en) 2006-02-09
WO2006013087A8 (en) 2007-03-01
BRPI0514124B8 (pt) 2021-05-25
KR20070047299A (ko) 2007-05-04
HRP20140888T1 (hr) 2014-10-24
BRPI0514124A (pt) 2008-05-27
NZ552637A (en) 2010-02-26
CN101001877A (zh) 2007-07-18
US20100254993A1 (en) 2010-10-07
ECSP077222A (es) 2007-03-29
CA2574289A1 (en) 2006-02-09
TWI356828B (en) 2012-01-21

Similar Documents

Publication Publication Date Title
CY1115524T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
IS7348A (is) N-pýrasínýl-fenýlsúlfónamíð og notkun þeirra til að meðhöndla flakkboðatengda sjúkdóma
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
ATE380007T1 (de) Dünne und trockene windel
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
ATE546463T1 (de) Modifizierte humane wachstumshormon-polypeptide und ihre verwendungen
ATE413178T1 (de) 2-phenoxy- und 2-phenylsulfanyl-benzenesulfonamid derivate mit ccr3 antagonistischer aktivität zur behandlung von asthma und anderen entzündlichen oder immunologischen erkrankungen
CA104919S (en) Air freshener device
DK1678194T3 (da) Modulering af syntese og degradering af hyaluronan i behandlingen af sygdom
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
DE602005006758D1 (de) Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
DE602004010785D1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE602004027354D1 (de) SUBSTITUIERTE 8y-PYRIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ON- UND 8y-PYRIMIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ONDERIVATE UND DEREN VERWENDUNG BEI NEURODEGENERATIVEN KRANKHEITEN
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
DE602005011818D1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
NO20053903D0 (no) Nukleotidlipidesterderivater.
DE60314003D1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
IS8390A (is) Notkun á gaboxadóli við meðhöndlun á svefnleysi
DE602006010337D1 (de) 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie
ATE420074T1 (de) Bengamide-derivate und deren verwendung zur behandlung von krebserkrankungen
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
FR2847430B1 (fr) Cendrier jetable et portable